Latest Schedule 13G passive stakes

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 8.0% of Scholar Rock Holding Corporation's common stock as of June 30, 2026.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed a Schedule 13G, reporting beneficial ownership of 5.01% of Huntsman Corp's common stock.

Rosalind Advisors Inc. and its affiliated entities have reported beneficial ownership of 9.9% of Regentis Biomaterials Ltd.'s common shares, primarily through warrants and existing shares.

Several entities affiliated with Invus Group and Raymond Debbane have collectively acquired a 6.0% stake in Abivax S.A., signaling a notable investment in the biopharmaceutical company.

Several Artal Group entities have updated their beneficial ownership filings for CAVA Group, Inc., reporting a 5.6% stake as of June 30, 2026.

Trium Capital LLP has disclosed beneficial ownership of 5.3% of RE/MAX Holdings, Inc. Class A Common Stock, signaling institutional interest.

Rosalind Advisors Inc. and related entities have reported beneficial ownership of 9.6% of Fennec Pharmaceuticals Inc. common shares as of June 30, 2026.

AQR Capital Management reports a beneficial ownership stake of 5.07% in Genpact LTD as of June 30, 2026.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Gartner Inc. common stock.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership of 125,261 shares, representing 9.99% of Silo Pharma, Inc.'s common stock.

Reporting Persons Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed beneficial ownership of 0% of Silexion Therapeutics Corp's ordinary shares as of June 30, 2026.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, have filed an amended Schedule 13G, reporting beneficial ownership of 9.99% of Sunshine Biopharma Inc. common stock.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, has disclosed beneficial ownership of approximately 8.2% of PowerCompute, Inc.'s common stock.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed an amendment to their Schedule 13G, reporting beneficial ownership of 7.21% of eHealth, Inc. common stock as of June 30, 2026.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, has reported beneficial ownership of approximately 9.0% of Longeveron Inc.'s Class A Common Stock.

Reporting persons, including Intracoastal Capital LLC, have adjusted their beneficial ownership of GeoVax Labs, Inc. common stock to 4.99%, triggering a Schedule 13G filing.

GRI Bio, Inc. reports a beneficial ownership update from Intracoastal Capital LLC and associated individuals, holding just under 5% of the company's common stock.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, has reported a beneficial ownership of 3.5% of Cemtrex Inc.'s common stock as of June 30, 2026, primarily through a warrant.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, reported a combined beneficial ownership of 4.8% in Artelo Biosciences, Inc. common stock as of June 30, 2026.

Several entities and individuals have jointly reported beneficial ownership of approximately 9.9% of Kandal M Venture Limited's Class A Ordinary Shares, acquired through convertible debt.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, has filed a Schedule 13G, reporting beneficial ownership of 632,752 shares of Change Agents Corporation's common stock, representing 4.99% of the outstanding shares.

AQR Capital Management, through its LLCs, has reported beneficial ownership of over 7.78 million shares, representing 5.07% of DoubleVerify Holdings, Inc. common stock.

A Schedule 13G filing reveals passive ownership of Aethelon Medical Inc. common stock by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC.

AQR Capital Management, through its entities, has increased its beneficial ownership of Concentrix Corp. common stock to 5.36%, holding over 3.27 million shares.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed a Schedule 13G, reporting beneficial ownership of 12,934,175 shares, representing 5.55% of Chewy, Inc.'s Class A Common Stock.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed an amendment to their Schedule 13G, reporting a beneficial ownership of 5.22% in BellRing Brands, Inc.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed an amendment to their Schedule 13G, reporting a beneficial ownership of 5.47% in Abercrombie & Fitch Co.

Zhang Xiaofan has filed a Schedule 13G, reporting beneficial ownership of 0.6% of Yarrow Bioscience, Inc. common stock.

AQR Capital Management, through its subsidiaries, has reported beneficial ownership of 6.21% of Irenic Acquisition Corp.'s Class A ordinary shares as of June 30, 2026.

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a change in their beneficial ownership of SITE Centers Corp. common shares, now holding 5.8% of the class.